Street Calls of the Week
Biodesix Inc (BDSX) stock has reached a new 52-week low, trading at $0.48, as the company faces ongoing market headwinds. According to InvestingPro data, despite strong revenue growth of 45.3% in the last twelve months, the stock appears undervalued based on its Fair Value analysis. This latest price point marks a significant downturn for the firm, which has seen its stock value decrease by 61.72% over the past year. Investors are closely monitoring Biodesix’s performance, as the company navigates through a challenging period marked by this notable decline in its stock price. The 52-week low serves as a critical indicator for shareholders and potential investors, reflecting the current market sentiment and the hurdles that Biodesix must overcome to regain its financial footing. With analysts setting price targets between $3.00 and $3.50, and a healthy current ratio of 2.76, detailed analysis and additional insights are available in the comprehensive Pro Research Report on InvestingPro.
In other recent news, Biodesix Inc. reported its fourth-quarter 2024 earnings, exceeding revenue expectations with a total of $20.4 million, surpassing the forecasted $19.87 million. The company also posted an earnings per share (EPS) of -$0.06, slightly better than the anticipated -$0.07. This marks a 39% year-over-year increase in revenue, driven primarily by a 43% rise in lung diagnostic testing revenue. For the full year 2024, Biodesix reported revenue of $71.3 million, a 45% increase compared to the previous year. The company plans to achieve adjusted EBITDA profitability in the second half of 2025, aiming for a revenue range of $92 to $95 million for that year. Biodesix is also expanding its sales force and engaging primary care physicians to increase its market reach. The company does not anticipate launching new tests in 2025, focusing instead on its existing offerings and strategic growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.